Abstract
The aim of this study was to assess the efficacy of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus. Type II diabetic patients exhibiting poor glycemic control following α-glucosidase inhibitor treatment for at least two months were selected and randomly distributed into vildagliptin and placebo groups. The body weight, fasting blood glucose (FBG), postprandial glucose (PPG), glycated hemoglobin (HBA1c) and blood lipid levels and hepatorenal functions of the patients were determined before and 12 weeks after the trial. Following the trial, the FBG, PPG, HbA1c, cholesterol (CHOL) and triglyceride (TG) levels in the vildagliptin group were significantly decreased compared with the pretreatment levels (P<0.05), whereas only the PPG level in the placebo group decreased (P<0.05). The FBG, PPG and HbA1c levels in the vildagliptin group were markedly lower than those in the placebo group 12 weeks after the trial. A comparison of the body weights and hepatorenal functions before and after the trial or between groups did not show statistically significant differences. The combination therapy of vildagliptin plus an α-glucosidase inhibitor effectively reduced the FBG, PPG and HbA1c levels in patients without inducing weight gain or hepatorenal dysfunction. However, the therapy may have caused a reduction in the blood lipid levels.
Highlights
The aim of this study was to assess the efficacy of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus
Vildagliptin binds to Dipeptidyl peptidase-4 (DPP-4) and forms a DPP-4 complex to inhibit DPP-4 activity, increase the levels of active glucagon‐like peptide-1 (GLP-1) and glucose-dependent insulin‐like peptide (GIP), promote insulin secretion by pancreatic β cells, and reduce glucagon secretion by α cells [9]
GLP-1 likely prevents the deterioration of diabetes and reduces the risk of weight gain by controlling the appetite to compensate for the negative effects of existing antihyperglycemic agents
Summary
The aim of this study was to assess the efficacy of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus. The body weight, fasting blood glucose (FBG), postprandial glucose (PPG), glycated hemoglobin (HBA1c) and blood lipid levels and hepatorenal functions of the patients were determined before and 12 weeks after the trial. The combination therapy of vildagliptin plus an α-glucosidase inhibitor effectively reduced the FBG, PPG and HbA1c levels in patients without inducing weight gain or hepatorenal dysfunction. A 12-week randomized controlled trial was performed in 520 patients with type II diabetes who exhibited poor glycemic control [HbA1c >6.5%, fasting blood glucose (FBG) >7.0 mmol/l] following α‐glucosidase inhibitor treatment between January 2012 and November 2012. The effects of a combination therapy of vildagliptin plus an α-glucosidase inhibitor on the fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c levels, body weight, blood lipid levels and hepatorenal functions of the patients were assessed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have